Efrat Dotan

8.5k total citations · 1 hit paper
134 papers, 2.9k citations indexed

About

Efrat Dotan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Efrat Dotan has authored 134 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 29 papers in Surgery. Recurrent topics in Efrat Dotan's work include Pancreatic and Hepatic Oncology Research (38 papers), Frailty in Older Adults (28 papers) and Colorectal Cancer Treatments and Studies (26 papers). Efrat Dotan is often cited by papers focused on Pancreatic and Hepatic Oncology Research (38 papers), Frailty in Older Adults (28 papers) and Colorectal Cancer Treatments and Studies (26 papers). Efrat Dotan collaborates with scholars based in United States, South Korea and France. Efrat Dotan's co-authors include Steven J. Cohen, Antoine Hollebecque, Do‐Youn Oh, Hui‐Ling Zhen, Gina M. Vaccaro, Mitesh J. Borad, Adrian Murphy, Vaibhav Sahai, Christine Lihou and Davide Melisi and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and Cancer.

In The Last Decade

Efrat Dotan

123 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

2020 975 citations Antoine Hollebecque, Mitesh J. Borad et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Efrat Dotan United States	23	1.6k	1.2k	706	681	433	134	2.9k
Anne Floquet France	30	1.3k 0.8×	665 0.6×	442 0.6×	758 1.1×	521 1.2×	170	3.3k
Mehmet Asım Bilen United States	34	2.1k 1.3×	1.1k 0.9×	921 1.3×	1.5k 2.3×	572 1.3×	317	4.1k
Thomas A. Abrams United States	25	1.4k 0.8×	655 0.6×	698 1.0×	668 1.0×	354 0.8×	84	2.4k
Luigi Manzione Italy	29	2.4k 1.5×	637 0.5×	386 0.5×	1.3k 1.9×	394 0.9×	88	3.4k
Giovanni Aletti Italy	41	809 0.5×	2.3k 1.9×	509 0.7×	516 0.8×	345 0.8×	119	4.9k
Emmanuel Gabriel United States	23	958 0.6×	850 0.7×	352 0.5×	525 0.8×	243 0.6×	121	1.9k
Felix Hilpert Germany	29	1.6k 1.0×	1.0k 0.9×	762 1.1×	477 0.7×	388 0.9×	172	3.9k
Radka Obermannová Czechia	18	1.4k 0.8×	1.1k 1.0×	429 0.6×	1.3k 2.0×	269 0.6×	60	2.6k
Tsuyoshi Konishi Japan	37	3.8k 2.3×	2.9k 2.5×	409 0.6×	1.2k 1.7×	198 0.5×	200	4.8k
Annamaria Ferrero Italy	32	1.2k 0.7×	1.2k 1.0×	375 0.5×	373 0.5×	429 1.0×	168	3.4k

Countries citing papers authored by Efrat Dotan

Since Specialization

Citations

This map shows the geographic impact of Efrat Dotan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Efrat Dotan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Efrat Dotan more than expected).

Fields of papers citing papers by Efrat Dotan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Efrat Dotan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Efrat Dotan. The network helps show where Efrat Dotan may publish in the future.

Co-authorship network of co-authors of Efrat Dotan

This figure shows the co-authorship network connecting the top 25 collaborators of Efrat Dotan. A scholar is included among the top collaborators of Efrat Dotan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Efrat Dotan. Efrat Dotan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sridharan, Anush, Efrat Dotan, Mengying Deng, et al.. (2025). Racial/Ethnic Differences and Effects of Clinical/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer. Journal of Gastrointestinal Cancer. 56(1). 67–67. 1 indexed citations

Chan, Sze Wah Samuel, et al.. (2025). Oncology: What You May Have Missed in 2024. Annals of Internal Medicine. 178(5_Supplement). S89–S109.

Aleixo, Gabriel, William R. Ferrell, Efrat Dotan, et al.. (2024). “Start low, go slow,” a strategy to tailor treatment dosing in older or vulnerable adults with advanced solid cancer: A systematic review and meta-analysis. Journal of Geriatric Oncology. 16(2). 102153–102153. 3 indexed citations

Dotan, Efrat, Paul J. Catalano, Leon Lenchik, et al.. (2024). A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.. Journal of Clinical Oncology. 42(16_suppl). 4003–4003. 4 indexed citations

Ahn, Eugene R., Michael Rothe, Pam K. Mangat, et al.. (2024). Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 1 indexed citations

Dotan, Efrat, et al.. (2024). Disparities in care of older adults of color with cancer: A narrative review. Cancer Medicine. 13(3). e6790–e6790. 4 indexed citations

Hollebecque, Antoine, Efrat Dotan, Chih‐Yi Liao, et al.. (2024). 58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study. European Journal of Cancer. 211. 114585–114585. 1 indexed citations

Fernandez, Sandra V., Shilpa Rao, Fathima Sheriff, et al.. (2023). Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing. International Journal of Molecular Sciences. 24(21). 15779–15779. 2 indexed citations

Jain, Rishi, Chethan Ramamurthy, Daohai Yu, et al.. (2023). Understanding the Challenges Faced by Esophageal and Gastroesophageal Junction Cancer Survivors. Journal of Patient Experience. 10. 672688921–672688921. 2 indexed citations

10.

Badri, Nabeel, Jason Zittel, Andrea Baran, et al.. (2023). Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.. Journal of Clinical Oncology. 41(16_suppl). 12047–12047. 1 indexed citations

11.

Sorice, Kristen A., Shannon M. Lynch, Edna Cukierman, et al.. (2023). Effects of losartan and vitamin D on outcomes in metastatic pancreatic adenocarcinoma.. Journal of Clinical Oncology. 41(4_suppl). 723–723.

12.

Dotan, Efrat, et al.. (2023). Guidance for Treating the Older Adults with Colorectal Cancer. Current Treatment Options in Oncology. 24(6). 644–666. 4 indexed citations

13.

Dotan, Efrat, et al.. (2023). Evidence-Based Care of Older Adults With Metastatic Colorectal Cancer: Insights From Landmark Clinical Trials. Journal of Clinical Oncology. 41(34). 5228–5236. 6 indexed citations

14.

Catalano, Paul, Steven J. Cohen, Barbara Burtness, et al.. (2023). Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial. The Oncologist. 28(9). 827–e822. 1 indexed citations

15.

Handorf, Elizabeth A., Ramya Varadarajan, Jack O. Hensold, et al.. (2022). Prospective Comparison of Geriatric Assessment and Provider’s Assessment of Older Adults With Metastatic Breast Cancer in the Community. The Oncologist. 27(2). e133–e141. 1 indexed citations

16.

Arisi, Maria F., Efrat Dotan, & Sandra V. Fernandez. (2022). Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer. International Journal of Molecular Sciences. 23(8). 4441–4441. 50 indexed citations

17.

Deng, Mengying, et al.. (2022). Assessing Oncologists’ Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data. JNCI Cancer Spectrum. 6(6). 5 indexed citations

18.

Dotan, Efrat, et al.. (2021). Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies. Drugs & Aging. 38(8). 639–654. 2 indexed citations

19.

Dotan, Efrat, William P. Tew, Supriya G. Mohile, et al.. (2020). Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumors. Cancer. 126(8). 1708–1716. 23 indexed citations

20.

Hyman, David M., Naiyer A. Rizvi, Ronald B. Natale, et al.. (2018). Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clinical Cancer Research. 24(12). 2749–2757. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact